Oxford Nanopore Technologies vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
UK nanopore sequencing pioneer with portable MinION device; £223M FY2025 revenue (+24% constant currency). Clinical revenues up 60% as sequencing moves to point-of-care.
About
Oxford Nanopore Technologies (ONT) was spun out of the University of Oxford in 2005, commercializing a radically different sequencing approach: passing DNA strands through biological nanopore proteins embedded in a membrane and detecting characteristic ionic current changes to call bases in real time. This enables ultra-long reads (megabase scale), direct RNA sequencing, and epigenetic base modification detection without prior amplification.\n\nONT's product range spans from the palm-sized MinION (the world's first portable DNA sequencer) to the high-throughput PromethION 2 Solo and PromethION 48 platforms. These instruments have enabled field sequencing for infectious disease outbreak response (COVID-19, mpox, Ebola), real-time clinical microbiology, plant pathogen surveillance, and cancer genomics. The company reported £223 million in FY2025 revenue, representing 24% constant-currency growth, with clinical revenues up 60% and biopharma revenues up 30%.\n\nONT is publicly listed on the London Stock Exchange and holds approximately £300 million in cash. While accuracy has historically lagged Illumina and PacBio, successive chemistry improvements and the Kit14 chemistry have closed the gap for many applications. The company is expanding its presence in clinical diagnostics, with regulatory filings underway in key markets, and remains the benchmark for portable, real-time, and long-read sequencing.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.